These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

483 related items for PubMed ID: 16213290

  • 1. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
    Sevmis S, Emiroglu R, Karakayali F, Yagmurdur MC, Dalgic A, Moray G, Haberal M.
    Transplant Proc; 2005 Sep; 37(7):3016-8. PubMed ID: 16213290
    [Abstract] [Full Text] [Related]

  • 2. One center's experience with antithymocyte globulin treatment for acute rejection in renal transplantation.
    Colak T, Sevmiş S, Karakayali H, Moray G, Haberal M.
    Transplant Proc; 2008 Sep; 40(1):123-5. PubMed ID: 18261564
    [Abstract] [Full Text] [Related]

  • 3. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
    Cantarovich M, Latter DA, Loertscher R.
    Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721
    [Abstract] [Full Text] [Related]

  • 4. How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation?
    Wagner FM, Reichenspurner H, Uberfuhr P, Kur F, Kaulbach HG, Meiser BM, Ziegler U, Reichart B.
    J Heart Lung Transplant; 1994 Aug; 13(3):438-42; discussion 442-3. PubMed ID: 8061020
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of OKT3 therapy for acute rejection in isolated lung transplantation.
    Shennib H, Massard G, Reynaud M, Noirclerc M.
    J Heart Lung Transplant; 1994 Aug; 13(3):514-9. PubMed ID: 8061029
    [Abstract] [Full Text] [Related]

  • 6. Predicting factors of long-term results of OKT3 therapy for steroid resistant acute rejection following cadaveric renal transplantation.
    Rostaing L, Chabannier MH, Modesto A, Rouzaud A, Cisterne JM, Tkaczuk J, Durand D.
    Am J Nephrol; 1999 Aug; 19(6):634-40. PubMed ID: 10592356
    [Abstract] [Full Text] [Related]

  • 7. Effect of OKT3 in steroid-resistant renal transplant rejection.
    Petrie JJ, Rigby RJ, Hawley CM, Suranyi MG, Whitby M, Wall D, Hardie IR.
    Transplantation; 1995 Feb 15; 59(3):347-52. PubMed ID: 7871563
    [Abstract] [Full Text] [Related]

  • 8. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
    Schroeder TJ, First MR, Mansour ME, Alexander JW, Penn I.
    Am J Kidney Dis; 1989 Nov 15; 14(5 Suppl 2):14-8. PubMed ID: 2510506
    [Abstract] [Full Text] [Related]

  • 9. Initial experience with tacrolimus rescue therapy in OKT3 resistant rejection.
    Herget S, Heemann U, Friedrich J, Kribben A, Wagner K, Philipp T.
    Clin Nephrol; 1996 May 15; 45(5):352-4. PubMed ID: 8738671
    [Abstract] [Full Text] [Related]

  • 10. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ, First MR, Hurtubise PE, Marmer DJ, Martin DM, Mansour ME, Melvin DB.
    J Heart Transplant; 1989 May 15; 8(5):371-80. PubMed ID: 2529358
    [Abstract] [Full Text] [Related]

  • 11. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
    Kehinde EO, Feehally J, Scriven SD, Veitch PS, Bell PR.
    Transplant Proc; 1996 Jun 15; 28(3):1449-50. PubMed ID: 8658735
    [No Abstract] [Full Text] [Related]

  • 12. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A, Nart A, Taşli FA, Postaci H, Aykas A, Doğan M, Sahin T.
    Nephrology (Carlton); 2008 Feb 15; 13(1):80-6. PubMed ID: 18199109
    [Abstract] [Full Text] [Related]

  • 13. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES, Bruce DS, Josephson M, Cronin D, Newell KA, Millis JM, Piper JB, O'Laughlin R, Thistlethwaite JR.
    Clin Transplant; 1996 Aug 15; 10(4):389-95. PubMed ID: 8884115
    [Abstract] [Full Text] [Related]

  • 14. Quadruple immunosuppression: comparison of OKT3 and Minnesota antilymphocyte globulin.
    Light JA, Khawand N, Aquino A, Ali A, Korb S.
    Am J Kidney Dis; 1989 Nov 15; 14(5 Suppl 2):10-3. PubMed ID: 2510505
    [Abstract] [Full Text] [Related]

  • 15. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
    Kahana L, Narvarte J, Ackermann J, LeFor W, Weinstein S, Wright C, deQuesada A, Baxter J, Shires D.
    Am J Kidney Dis; 1989 Nov 15; 14(5 Suppl 2):5-9. PubMed ID: 2510510
    [Abstract] [Full Text] [Related]

  • 16. Impact of first acute rejection episode and severity of rejection on cadaveric renal allograft survival.
    Hariharan S, Alexander JW, Schroeder TJ, First MR.
    Clin Transplant; 1996 Dec 15; 10(6 Pt 1):538-41. PubMed ID: 8996775
    [Abstract] [Full Text] [Related]

  • 17. Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients.
    Kumano K, Irie A, Mashimo S, Endo T, Koshiba K.
    Transplant Proc; 1996 Jun 15; 28(3):1354-5. PubMed ID: 8658691
    [No Abstract] [Full Text] [Related]

  • 18. Impact of Banff borderline acute rejection among renal allograft recipients.
    Matoza JR, Danguilan RA, Chicano S.
    Transplant Proc; 2008 Sep 15; 40(7):2303-6. PubMed ID: 18790219
    [Abstract] [Full Text] [Related]

  • 19. Tacrolimus: a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation.
    Meiser BM, Uberfuhr P, Fuchs A, Schulze C, Nollert G, Mair H, Martin S, Pfeiffer M, Reichenspurner H, Kreuzer E, Reichart B.
    J Heart Lung Transplant; 1997 Aug 15; 16(8):795-800. PubMed ID: 9286771
    [Abstract] [Full Text] [Related]

  • 20. Antimouse antibody response after OKT3 administration for steroid resistant rejection.
    Kaiser BA, Palmer JA, Dunn SP, Mochon MA, Bartosh SM, Schulman SL, Polinsky MS, Baluarte HJ.
    Child Nephrol Urol; 1991 Aug 15; 11(4):190-2. PubMed ID: 1777898
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.